Tandem Diabetes Care Inc Market Cap ($1.18 Billion)
Market Cap & Net Worth: Tandem Diabetes Care Inc (TNDM)
Tandem Diabetes Care Inc market cap. Tandem Diabetes Care Inc (NASDAQ:TNDM) has a market capitalization of $1.18 Billion ($1.18 Billion) as of November 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7934 globally and #2367 in its home market, demonstrating a -14.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tandem Diabetes Care Inc's stock price $16.91 by its total outstanding shares 69578707 (69.58 Million). Also see Tandem Diabetes Care Inc (TNDM) cash conversion ratio for how efficiently the company converts equity into cash flow.
Tandem Diabetes Care Inc Market Cap History (2015–2026)
Tandem Diabetes Care Inc market cap history from 2015 to 2026. Data shows change from $8.22 Billion to $1.18 Billion (-13.26% CAGR). Check latest Tandem Diabetes Care Inc stock price today for real-time trading data and today's change.
Index Memberships
Tandem Diabetes Care Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.05% | #229 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.00% | #873 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.51 Trillion | 0.10% | #429 of 602 |
Weight: Tandem Diabetes Care Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tandem Diabetes Care Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tandem Diabetes Care Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Tandem Diabetes Care Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.51x
Tandem Diabetes Care Inc's market cap is 1.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.50 Billion | $84.25 Million | -$83.45 Million | 17.76x | N/A |
| 2017 | $164.21 Million | $107.60 Million | -$73.03 Million | 1.53x | N/A |
| 2018 | $2.64 Billion | $183.87 Million | -$122.61 Million | 14.37x | N/A |
| 2019 | $4.15 Billion | $362.31 Million | -$24.75 Million | 11.45x | N/A |
| 2020 | $6.66 Billion | $498.83 Million | -$34.38 Million | 13.35x | N/A |
| 2021 | $10.47 Billion | $702.80 Million | $15.57 Million | 14.90x | 672.81x |
| 2022 | $3.13 Billion | $801.22 Million | -$94.59 Million | 3.90x | N/A |
| 2023 | $2.06 Billion | $747.72 Million | -$222.61 Million | 2.75x | N/A |
| 2024 | $2.51 Billion | $940.20 Million | -$96.03 Million | 2.67x | N/A |
| 2025 | $1.53 Billion | $1.01 Billion | -$204.71 Million | 1.51x | N/A |
Competitor Companies of TNDM by Market Capitalization
Companies near Tandem Diabetes Care Inc in the global market cap rankings as of November 7, 2026. Also see how large is Tandem Diabetes Care Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to Tandem Diabetes Care Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #109 globally with a market cap of $191.15 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #188 globally with a market cap of $124.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #222 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #109 | Abbott Laboratories | NYSE:ABT | $191.15 Billion | $109.93 |
| #188 | Stryker Corporation | NYSE:SYK | $124.99 Billion | $325.87 |
| #222 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $101.80 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Tandem Diabetes Care Inc (2015–2026)
Market capitalization of Tandem Diabetes Care Inc from 2015 to today. Between 2015 and today, Tandem Diabetes Care Inc's market cap moved from $8.22 Billion to $ 1.18 Billion, with a yearly change of -13.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.18 Billion | -23.07% |
| 2025 | $1.53 Billion | -38.98% |
| 2024 | $2.51 Billion | +21.77% |
| 2023 | $2.06 Billion | -34.19% |
| 2022 | $3.13 Billion | -70.14% |
| 2021 | $10.47 Billion | +57.32% |
| 2020 | $6.66 Billion | +60.51% |
| 2019 | $4.15 Billion | +56.99% |
| 2018 | $2.64 Billion | +1508.90% |
| 2017 | $164.21 Million | -89.02% |
| 2016 | $1.50 Billion | -81.80% |
| 2015 | $8.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Tandem Diabetes Care Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.18 Billion USD |
| MoneyControl | $1.18 Billion USD |
| MarketWatch | $1.18 Billion USD |
| marketcap.company | $1.18 Billion USD |
| Reuters | $1.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more